Impact of psychiatric comorbidities in psoriasis, hidradenitis suppurativa and atopic dermatitis: The importance of a psychodermatological approach

Michela Iannone1 | Agata Janowska1 | Salvatore Panduri1 | Riccardo Morganti2 | Giulia Davini1 | Marco Romanelli1 | Valentina Dini1

1Department of Dermatology, University of Pisa, Pisa, Italy
2Department of Clinical and Experimental Medicine, Section of Statistics, University of Pisa, Pisa, Italy

Correspondence
Michela Iannone, Department of Dermatology, University of Pisa, Via Roma, 67 56126, Pisa Italy.
Email: drmichelaiannone@gmail.com

Abstract
Background: There is a strong interaction between the immunological and nervous system in the skin. Lesions that are physically disfiguring and chronically relapsing have a high impact on quality of life (QoL) and can result in the emergence of psychiatric disorders. The literature data confirm a higher prevalence of psychiatric disorders in patients with psoriasis, hidradenitis suppurativa (HS) and atopic dermatitis (AD), but such data are compromised by low-quality evidence due to methodological heterogeneity.

Objectives: The primary aim was to analyse the prevalence of psychiatric comorbidities in a group of psoriasis, AD and HS patients compared with a control group. The secondary aims were to evaluate the impact of psychiatric comorbidities on the disease development, severity, flare-ups and QoL.

Methods: A total of 59 cases and 64 controls were included.

Results: Generalized anxiety disorder and depressive disorder with anxious distress were found to be risk factors for AD. Age, smoking and substance-related disorder showed a specific association with HS. Major depressive disorder showed a specific association with dermatology life quality index (DLQI) and all the above disease flare-ups.

Conclusions: Atopic dermatitis, psoriasis and HS are associated with psychiatric disorders. A psychodermatological approach improves outcomes in terms of QoL, disease flare-ups and long-term management.

Keywords
atopic dermatitis, hidradenitis suppurativa, inflammatory skin disease, psoriasis, psychiatric comorbidity, psychodermatological approach, psychological burden
1 | BACKGROUND

There is a strong interaction between the immunological and nervous system in the skin. This relationship is investigated by psychoneuroimmunology and can be divided into three different types: (1) psychophysiologic disorders; (2) primitive psychiatric disorders and (3) secondary psychiatric disorders. Anxiety disorder is the most common primary psychiatric disorder in patients with chronic inflammatory skin diseases, with a prevalence of 17.2%. Secondary psychiatric disorders can alter the quality of life (QoL) of patients, with reactive depression, anxiety, social isolation and suicidal ideation. In chronic inflammatory skin diseases, particularly psoriasis, hidradenitis suppurativa (HS) and atopic dermatitis (AD), patients often have physically disfiguring lesions associated with itching, sleep disturbance, excoriation or bleeding with a chronic relapsing course characterized by unpredictable flare-ups and difficult triggers to prevent. Such pathologies require an adaptation to living with the disease, which can generate psychiatric disorders.

Psoriasis is a chronic inflammatory skin disease characterized by an immune dysfunction of the Th1/Th17 axis. The first studies on the association between psoriasis and anxiety, depression and suicidal ideation were published at the end of the 1970s. A systematic review of the literature from 1990 to 2015 confirmed the association of psoriasis with anxiety and depression. It also highlighted other comorbidities, such as eating disorders, psychotic disorders, personality disorders, sexual dysfunction, sleep disturbances, somatoform disorders and substance abuse. Another comprehensive qualitative review on psoriasis and psychiatric comorbidities since 2005 confirmed the findings given in but highlighted the poor quality of the data due to methodological heterogeneity (different mental health questionnaires, patients' self-reported online surveys and several confounders). Although no reliable biomarkers exist for psychiatric disorders, clinical examination combined with structured interviews and diagnostic tools relying on the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria allows to make a precise diagnosis.

Atopic dermatitis (AD) is a chronically relapsing skin disease. Clinical hallmarks are intense itching and eczematous lesions, with a significant impact on daily life. The association of AD with depression, anxiety and suicidal ideation was confirmed by a systematic review and meta-analysis published in 2018. The main limitation of this latter study was the definition of depression and anxiety based on self-reported symptoms and not on clinical psychiatric diagnoses. Moreover, few studies have examined the disease's severity.

Hidradenitis suppurativa (HS) is a chronic skin disease, characterized by recurrent and painful nodules, abscesses and sinus tracts involving the hair follicle. Living with HS indefinitely has a high physical and social impact: the presence of draining malodorous lesions in sensitive areas of the body has been described by patients as “miserable and horrible”. The first study on the association between HS and psychiatric disorders was published in 2012: depression, anxiety, bipolar disorder, psychoses, schizophrenia, substance abuse disorders and suicidal ideation are more common in HS patients than healthy individuals. Patients affected by HS also have an alexithymic personality trait, which leads to the frequent development of generalized anxiety disorder or depression. A systematic review and meta-analysis of the literature regarding the association between HS and psychiatric comorbidities revealed poor methodological quality and different clinical criteria for defining psychiatric comorbidities in published studies. These associations limit the prevalence of the comorbidities reported.

2 | QUESTIONS ADDRESSED

The primary aim was to analyse the prevalence of psychiatric comorbidities in a skin disease population compared with a control group. The secondary aims were to evaluate the impact of psychiatric comorbidities on disease development, severity, flare-ups and QoL.

3 | EXPERIMENTAL DESIGN

This retrospective study was performed in accordance with the Declaration of Helsinki and was approved by the Institutional Ethics Committee. We recruited adult patients diagnosed with psoriasis (20), HS (23) and AD (16) from February 2016 to October 2020. Patients were divided into two groups: cases with chronic inflammatory skin diseases and psychiatric comorbidities (depressive disorder with anxious distress; major depressive disorder; generalized anxiety disorder; substance-related disorder; bipolar disorder; diagnosed and treated by the psychiatrist in accordance with DSM-5 criteria) and controls with AD, HS or psoriasis without psychiatric comorbidities. Controls were matched for sex, age and disease severity to minimize the study bias.

Individual patient data were collected in open-access databases with the following structure: patient initials, sex, age, disease severity (Psoriasis Area Severity Index (PASI) or Eczema Area Severity Index (EASI) or mSartorius), mean flare-ups in the past 6 months, DLQI, current therapies and psychiatric comorbidities. The data were then entered into a single Excel file and subjected to descriptive and multivariate statistical analysis using SPSS v.25 software. Statistical significance was assessed in terms of p-value and odds ratio.

4 | RESULTS

A total of 59 cases and 64 controls were included. Table 1 reports the characteristics of the population.

The prevalence of psychiatric comorbidities was 13.90% in patients with psoriasis, 14.90% in HS patients and 19.8% in DA patients. Table 2 shows the results of the multivariate binary logistic regression analysis performed using a stepwise method to assess the impact of psychiatric comorbidities, gender, age and smoking on dependent variables such as inflammatory skin diseases (DA, HS, etc.)...
and psoriasis), objective disease score (PASI for psoriasis/EASI for atopic dermatitis/mSartorius for HS), DLQI and on disease flare-ups. Objective disease scores were dichotomized into mild (<10) and moderate-to-severe (≥10); DLQI was dichotomized into <12, ≥12 and disease flare into <3, ≥3 and then subjected to binary logistic regression.

All the comorbidities such as smoking, age, gender and psychiatric comorbidities were defined as independent variables and coded as follows: 0 = no; 1 = yes. Dermatologic diseases (AD, HS and psoriasis) were also coded in the same manner.

Generalized anxiety disorder and depressive disorder with anxious distress were found to be risk factors for AD development. None of the above variables showed a specific association with psoriasis. Age, smoking and substance-related disorder showed a specific association with HS development. Major depressive disorder showed a specific association with DLQI and disease flare-ups. None of the above independent variables impacted on objective disease scores. The statistical significance of the impacting variables is summarized in Table 3.

5 | DISCUSSION

Many studies on psoriasis, HS and AD are extremely heterogeneous and use self-administered questionnaires for the diagnosis of psychiatric comorbidities (such as Hospital Anxiety and Depression Scale, General Health Questionnaire-28, Hamilton Anxiety Rating Scale, Epidemiological Studies Depression Scale, etc.). Self-administered questionnaires highlight the symptoms of the anxiety or depressive spectrum but are not diagnostic with a high risk of false positives, poor-quality evidence and an overestimation of the prevalence of psychiatric comorbidities. 9,11,17

Our results showing the non-impact of psychiatric comorbidities on psoriasis differ from those in the literature, which show an increased risk of depression, anxiety and suicidality in psoriasis patients. 18,19 This could be related to the strong bias in the interpretation of the published data for the different clinical criteria and the utilization of self-administered questionnaires for the diagnosis of psychiatric comorbidities. The use of a common methodology and more studies on patients with specialist-confirmed psychiatric diagnoses will help clarify the bias between psychological/psychiatric spectrum symptoms and true psychiatric comorbidities.

Our results on HS patients are in line with those reported by a Danish case-control study that found no significant differences in the prevalence of depression in the two analysed groups. 14 Other studies confirmed an association between HS, anxiety and depression; however, the severity of the disease was not considered in the selection of patients. It cannot be excluded that the selected patients all had severe forms of the disease and that the results are a consequence of the poor prognosis. Since the studies were cross-sectional, the cause-effect relationship cannot be defined. 20,21

Results on substance-related disorder in HS patients should be contextualized in terms of the contrasting literature data: according to some authors, the association is significant, whereas for others, the concurrence of other psychiatric comorbidities reduces the significance of the association. In our patients, the association with a psychiatric comorbidity was found only in one case. Further studies are needed to clarify these data.

Our results on AD confirm an association with generalized anxiety disorder and major depressive disorder. The association with generalized anxiety disorder is in accordance with the literature data that define this disorder as "epiphenomenon indicative of hyperactivity of the hypothalamic-pituitary-adrenal axis." 3,22 The chronic hyperactivation of this axis induces an increase in the diurnal cortisol secretion, mast cells and eosinophil activation and the isotypic switch of B lymphocytes into IgE-secreting cells promoting a Th2-type inflammation. 1,4,23-25 Further studies are needed.
to verify whether this finding is repeatable for other atopic march comorbidities.

In both psoriasis and HS and AD patients, the impact of major depressive disorder on median DLQI values proved to be statistically significant, while there was no impact on disease objectivity. This finding has been reported in patients with psoriasis, HS and AD, but also with other chronic inflammatory diseases.\(^{26-29}\) In order to improve the outcomes, it is, therefore, essential to evaluate the patient’s subjective perception of the disease and then to correct and prevent depressive symptoms through group therapy, adjuvant training or the analysis of predisposing factors.\(^{30}\)

Major depressive disorder also impacts on flare-ups of the chronic inflammatory diseases under study. The concept of flares in the literature is highly variable. We considered a flare of HS as “an

| TABLE 2 Results of multivariate binary logistic regression analysis with stepwise method (statistically significant data highlighted in yellow) |
|---------------------------------------------------------------|
| **Dependent variable: atopic dermatitis (no, yes)**          |
| Phase 1                                                       |
| Smoke: -1.933, p-value: 0.000, OR: 0.145, IC 95% per OR:       |
| Costant: -0.215, p-value: 0.424, OR: 0.806, IC 95% per OR:       |
| Phase 2                                                       |
| Smoke: -2.051, p-value: 0.000, OR: 0.129, IC 95% per OR:       |
| Depressive_Disorder_Anxious_Distress: 1.851, p-value: 0.011, OR: |
| Costant: -0.394, p-value: 0.163, OR: 0.674, IC 95% per OR:       |
| Phase 3                                                       |
| Smoke: -2.283, p-value: 0.000, OR: 0.102, IC 95% per OR:       |
| Depressive_Disorder_Anxious_Distress: 2.110, p-value: 0.000, OR: |
| Generalized_Anxiety_Distress: 1.655, p-value: 0.019, OR:       |
| Costant: -0.576, p-value: 0.055, OR: 0.562, IC 95% per OR:       |
| **Dependent variable: Psoriasis (no, yes)**                   |
| Phase 1                                                       |
| Age: 0.045, p-value: 0.000, OR: 1.047, IC 95% per OR:          |
| Costant: -2.674, p-value: 0.000, OR: 0.069, IC 95% per OR:       |
| **Dependent variable: Hidradenitis (no, yes)**                |
| Phase 1                                                       |
| Smoke: 1.802, p-value: 0.000, OR: 6.065, IC 95% per OR:        |
| Costant: -1.653, p-value: 0.000, OR: 0.191, IC 95% per OR:       |
| Phase 2                                                       |
| Age: -0.060, p-value: 0.000, OR: 0.942, IC 95% per OR:         |
| Smoke: 2.551, p-value: 0.000, OR: 12.821, IC 95% per OR:        |
| Costant: 0.450, p-value: 0.042, OR: 1.569, IC 95% per OR:        |
| Phase 3                                                       |
| Age: -0.060, p-value: 0.000, OR: 0.942, IC 95% per OR:         |
| Smoke: 2.439, p-value: 0.000, OR: 11.460, IC 95% per OR:        |
| Substance_Related_Distress: 2.969, p-value: 0.072, OR:         |
| Costant: 0.431, p-value: 0.467, OR: 1.540, IC 95% per OR:        |
| **Dependent variable: Dermatology Life quality INDEX (<12, ≥12)** |
| Phase 1                                                       |
| Major_Depressive_Disorder: 2.412, p-value: 0.002, OR: 11.152, IC |
| Costant: 0.214, p-value: 0.279, OR: 0.807, IC 95% per OR:       |
| **Dependent variable: disease flares (<3, ≥3)**               |
| Phase 1                                                       |
| Major_Depressive_Disorder: 1.637, p-value: 0.013, OR: 5.142, IC |
| Costant: 0.097, p-value: 0.622, OR: 1.102, IC 95% per OR:       |
| **Dependent variable: objective disease scores (mild<10, moderate-to-severe≥10)** |
| Phase 1                                                       |
| Smoke: 1.289, p-value: 0.001, OR: 3.630, IC 95% per OR:       |
| Costant: -0.288, p-value: 0.287, OR: 0.750, IC 95% per OR:       |
association between disease severity and depression was reported in a German paper on psoriasis, in which, however, severity was estimated according to the number of medical visits in relation to the disease made by the patient. For AD, several studies associate psychological distress with major disease severity but no correlation with psychiatric comorbidities is described.

The limitations of our study are the monocentricity and the small sample, which restrict the generalization of data. The strengths include the selection of patients with psychiatric comorbidities according to DSM-5 criteria (diagnosed and treated by the psychiatrist), the assessment of dermatological diagnoses in a third-level hospital and the selection of the case-control population based on age, sex and disease severity in order to minimize bias. In contrast with other studies on large registry-based populations, this enabled us to evaluate the absence of an association between disease severity and psychiatric comorbidities, that is data not currently reported in the literature.

6 | CONCLUSIONS AND PERSPECTIVES

The closest interaction between the nervous and immunological systems in the skin occurs through a complex mix of psychosocial factors and psychiatric disorders. Chronic inflammatory skin diseases, particularly AD, psoriasis and HS, can cause psychiatric disorders. In order to improve the outcomes in terms of QoL, disease flare-ups and long-term management, we recommend that the medical therapy should be combined with a psychodermatological approach through strategies ranging from psychotherapy to pharmacotherapy, in collaboration with the specialist psychologist/psychiatrist.

The development of a common methodology with more studies on dermatological patients with specialist-confirmed psychiatric comorbidities is needed in order to clarify the bias between psychiatric spectrum symptoms and psychiatric comorbidities in chronic inflammatory skin diseases. Prospective studies and clinical trials are needed to clarify the cause-and-effect relationships and to determine whether monitoring psychiatric comorbidities can improve patient perception of illness and reducing disease flares.

ACKNOWLEDGEMENTS

Open access publishing facilitated by Universita degli Studi di Pisa, as part of the Wiley -Universita degli Studi di Pisa via the Conference of Rectors of Italian Universities.

CONFLICT OF INTEREST

The research reported in this article has not received external funding. No competing financial interests exist. The authors have no conflicts of interest to declare.

AUTHOR CONTRIBUTIONS

Michela Iannone, Salvatore Panduri, Riccardo Morganti, Giulia Davini and Agata Janowska contributed to the conception and design, acquisition of data, analysis and interpretation of data. Valentina Dini

TABLE 3 Statistical significance of independent variables impacting on dermatologic diseases

| Variables                              | Atopic dermatitis | p-value |
|----------------------------------------|-------------------|---------|
| Smoke                                  |                   |         |
| Not                                    | 31 (19)           |         |
| Yes                                    | 60 (15)           |         |
| Depressive disorder with anxious distress | Not 86 (25) | 0.007 |
| Yes                                    | 5 (7)             |         |
| Generalized anxiety disorder           | Not 82 (25)       | 0.083 |
| Yes                                    | 9 (7)             |         |
| Substance-related disorder             |                  |         |
| Not                                    | 77 (39)           | 0.005  |
| Yes                                    | 1 (6)             |         |
| DLQI < 12                              |                   |         |
| Smoke                                  |                   |         |
| Not                                    | 37 (19)           | 0.0002 |
| Yes                                    | 22 (45)           |         |
| Major depressive disorder              |                  |         |
| Not                                    | 57 (46)           | 0.0002 |
| Yes                                    | 2 (18)            |         |
| Flares < 3                             |                   |         |
| Major depressive disorder              |                  |         |
| Not                                    | 49 (54)           | 0.007  |
| Yes                                    | 3 (17)            |         |

acute development of at least one inflammatory lesion or the recurrence of a previous lesion; a flare of psoriasis/AD as “a worsening of PASI/EASI by at least 25% from baseline.”

The association between major depressive disorder and flare-ups of chronic inflammatory diseases is not reported in the literature. The neuroinflammatory hypothesis is one of the possible explanations for this association. More specifically, the excess of proinflammatory cytokines involved in the flare-ups reduces the neurotrophic support with altered uptake/release of glutamate, consequent cytotoxicity and loss of glial elements, in line with the neuropathological findings that characterize depressive disorders.

Our results showed that psychiatric comorbidities had no impact on disease severity, assessed in terms of PASI, EASI and mSartorius. There are little data on this topic in the literature. A possible...
and Marco Romanelli were involved in drafting the manuscript and revised it critically for important intellectual content.

**INFORMED CONSENT**

The submitting author has the written consent from all authors to submit the manuscript. All authors have participated sufficiently in the work to take public responsibility for appropriate portions of the content and accept complete responsibility for the contents of the manuscript. The authors have agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The authors warrant that the article is original, is not under consideration by another journal and has not been previously published.

**ORCID**

Michela Iannone https://orcid.org/0000-0002-1463-0017

**REFERENCES**

1. Tausk F, Elenkov I, Moynihan J. Psychoneuroimmunology. *Dermatol Ther*. 2008;21:22-31.
2. Honeyman JF. Psychoneuroimmunology and the Skin. *Acta Derm Venereol*. 2016;96:38-46.
3. Dalgaard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. *J Invest Dermatol*. 2015;135:984-991.
4. Peters EM. Stressed skin?–a molecular psycosomatic update on stress-causes and effects in dermatologic diseases. *J Dtsch Dermatol Ges*. 2016;14:233-252.
5. Griffiths CE, Barker JN. Pathogenesis and clinical features of psoriasis. *Lancet*. 2007;370:263-271.
6. Savin JA. Patients’ beliefs about psoriasis. *Trans St Johns Hosp Dermatol Soc*. 1970;56:139-142.
7. Gupta MA, Schork NJ, Gupta AK, Kirkby S, Ellis CN. Suicidal ideation in psoriasis. *Int J Dermatol*. 1993;32:188-190.
8. Ferreira BI, Abreu JL, Reis JP, Figueiredo AM. Psoriasis and associated psychiatric disorders: a systematic review on etiopathogenesis and clinical correlation. *J Clin Aesthet Dermatol*. 2016;9:36-43.
9. Rieder E, Tausk F. Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and treatments. *Int J Dermatol*. 2012;51:12-26.
10. Iannone M, Tonini G, Janowska A, Dini V, Romanelli M. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: a systematic review. *Curr Med Res Opin*. 2021;37(8):1295-1301.
11. Renstad ATM, Halling-Overgaard AS, Hamann CR, Skov L, Egeberg A, Thyssen JP. Association of atopic dermatitis with depression, anxiety, and suicidal ideation in children and adults: a systematic review and meta-analysis. *J Am Acad Dermatol*. 2018;79:448-456.
12. Iannone M, Oranges T, Chiricozzi A, De Tata V, Romanelli M, Dini V. Potential role of serum amyloid A in hidradenitis suppurativa. *JAAD Case Rep*. 2019;5:406-409.
13. Experience Project Website. I have hidradenitis suppurativa. Me too. Accessed August 17, 2015. [http://www.experienceproject.com/groups/Have-Hidradenitis-Suppurativa/36845](http://www.experienceproject.com/groups/Have-Hidradenitis-Suppurativa/36845).
14. Onderdijk AJ, van der Zee HH, Es mann S, et al. Depression in patients with hidradenitis suppurativa. *J Eur Acad Dermatol Venereol*. 2013;27:473-478.
15. Misitzis A, Goldust M, Jafferany M, Lotti T. Psychiatric comorbidities in patients with hidradenitis suppurativa. *Dermatol Ther*. 2020;33:e13541.
16. Chiricozzi A, Giovanardi G, Caro DRC, et al. Alexithymia affects patients with hidradenitis suppurativa. *Eur J Dermatol*. 2018;28:482-487.
17. Machado MO, Stergiopoulos V, Maes M, et al. Depression and anxiety in adults with hidradenitis suppurativa: a systematic review and meta-analysis. *JAMA Dermatol*. 2019;155:939-945.
18. Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. *Arch Dermatol*. 2010;146:891-895.
19. Schmitt J, Ford DE. Psoriasis is independently associated with psychiatric morbidity and adverse cardiovascular risk factors, but not with cardiovascular events in a population-based sample. *J Eur Acad Dermatol Venereol*. 2010;24:885-892.
20. Shavit D, Dreher J, Freud T, Halevy S, Vinker S, Cohen AD. Psychiatric comorbidities in 3207 patients with hidradenitis suppurativa. *J Eur Acad Dermatol Venereol*. 2015;29:371-376.
21. Huilaja L, Tiri H, Jokelainen J, Timonen M, Tasanen K. Patients with hidradenitis suppurativa have a high psychiatric disease burden: a Finnish Nationwide Registry Study. *J Invest Dermatol*. 2018;138:46-51.
22. Thyssen JP, Hamann CR, Linneberg A, et al. Atopic dermatitis is associated with anxiety, depression, and suicidal ideation, but not with psychiatric hospitalization or suicide. *Allergy*. 2018;73:214-220.
23. Vedhara K, Fox JD, Wang EC. The measurement of stress related immune dysfunction in psychoneuroimmunology. *Neurosci Biobehav Rev*. 1999;23:699-715.
24. Montoro J, Mullol J, Jäuregui I, et al. Stress and allergy. *J Investig Allerg Clin Immunol*. 2009;19:40-47.
25. Allen SJ, Dawbarn D. Clinical relevance of the neurotrophins and their receptors. *Clin Sci*. 2006;110:175-191.
26. Malmutovic J, Zukic M, Pasalic A, Brkanovic S, Jaganjac A, Katana B. Correlation between quality of life and depression among persons suffering from psoriasis. *Med Arch*. 2017;71:341-346.
27. Jemec GB. Quality of life considerations and pain management in hidradenitis suppurativa. *Semin Cutan Med Surg*. 2017;36:75-78.
28. Kwak Y, Kim Y. Health-related quality of life and mental health of adults with atopic dermatitis. *Arch Psychiatr Nurs*. 2017;31:516-521.
29. Pirna E, Alouja A, Kingo K. Quality of life and emotional state in chronic skin disease. *Acta Derm Venereol*. 2015;95:312-316.
30. Kirby JS, Butt M, Esmann S, Jemec GBE. Association of resilience with depression and health-related quality of life for patients with hidradenitis suppurativa. *JAMA Dermatol*. 2017;153:1263-1269.
31. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. *Biol Psychiatry*. 2009;65:732-741.
32. Devrimci-Ozguzen H, Kundakci TN, Kumbasar H, Boyvat A. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. *J Eur Acad Dermatol Venereol*. 2000;14:267-271.
33. Kim SH, Hur J, Jang JY, et al. Psychological distress in young adult males with atopic dermatitis: a cross-sectional study. *Medicine (Baltimore)*. 2015;94:e949.

**How to cite this article**: Iannone M, Janowska A, Panduri S, et al. Impact of psychiatric comorbidities in psoriasis, hidradenitis suppurativa and atopic dermatitis: The importance of a psychodermatological approach. *Exp Dermatol*. 2022;31:956-961. doi:10.1111/exd.14563